These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
177 related articles for article (PubMed ID: 31527930)
41. Monitoring anti-HIV medicines: what is the FDA's role? Mirken B BETA; 2001; 14(1):8-11. PubMed ID: 11695333 [No Abstract] [Full Text] [Related]
42. The FDA's generic-drug approval process: similarities to and differences from brand-name drugs. Kefalas CH; Ciociola AA Am J Gastroenterol; 2011 Jun; 106(6):1018-21. PubMed ID: 21637264 [No Abstract] [Full Text] [Related]
43. Surrogate Endpoints and Drug Regulation: What Is Needed to Clarify the Evidence. Hey SP; Feldman WB; Jung EH; D'Andrea E; Kesselheim AS J Law Med Ethics; 2019 Sep; 47(3):381-387. PubMed ID: 31560631 [TBL] [Abstract][Full Text] [Related]
44. Flexibility and innovation in the FDA's novel regulatory approval strategies for hematologic drugs. Farrell AT; Goldberg KB; Pazdur R Blood; 2017 Sep; 130(11):1285-1289. PubMed ID: 28774876 [No Abstract] [Full Text] [Related]
47. Expediting drug development--the FDA's new "breakthrough therapy" designation. Sherman RE; Li J; Shapley S; Robb M; Woodcock J N Engl J Med; 2013 Nov; 369(20):1877-80. PubMed ID: 24224621 [TBL] [Abstract][Full Text] [Related]
48. [FDA's new drug approval system]. Ishii A Gan To Kagaku Ryoho; 1995 Aug; 22(9):1146-51. PubMed ID: 7661565 [No Abstract] [Full Text] [Related]
49. Industry funding of the FDA: effects of PDUFA on approval times and withdrawal rates. Berndt ER; Gottschalk AH; Philipson TJ; Strobeck MW Nat Rev Drug Discov; 2005 Jul; 4(7):545-54. PubMed ID: 16052239 [TBL] [Abstract][Full Text] [Related]
50. Second thoughts: do the FDA's responses to a fatal drug trial and the AIDS activist community's doubts about early access to drugs hint at a shift in basic FDA policy? Lovell MC Food Drug Law J; 1996; 51(2):273-94. PubMed ID: 11820202 [No Abstract] [Full Text] [Related]
51. Catalyzing the Critical Path Initiative: FDA's progress in drug development activities. Parekh A; Buckman-Garner S; McCune S; ONeill R; Geanacopoulos M; Amur S; Clingman C; Barratt R; Rocca M; Hills I; Woodcock J Clin Pharmacol Ther; 2015 Mar; 97(3):221-33. PubMed ID: 25670629 [TBL] [Abstract][Full Text] [Related]
52. Vision and will: the future of the FDA. Epstein D Oncologist; 2009 Apr; 14(4):317-9. PubMed ID: 19365098 [No Abstract] [Full Text] [Related]
56. Aducanumab, Accelerated Approvals & the Agency: Why the FDA Needs Structural Reform. Herder M J Law Med Ethics; 2023; 51(4):900-919. PubMed ID: 38477277 [TBL] [Abstract][Full Text] [Related]
57. They are from the government and they really are here to help you. Woosley RL J Clin Pharmacol; 2008 Feb; 48(2):142-3. PubMed ID: 18199889 [No Abstract] [Full Text] [Related]
58. FDA notifications. FDA's tentative approval for generic Tenofovir. AIDS Alert; 2008 Jan; 23(1):11-2. PubMed ID: 18572475 [No Abstract] [Full Text] [Related]
59. A Food and Drug Administration primer. Simon LS Arthritis Rheum; 2006 Feb; 55(1):4-8. PubMed ID: 16463403 [No Abstract] [Full Text] [Related]
60. Legal and regulatory developments of the 1990s in oral care products: learning from what has come before. O'Reilly JT J Public Health Dent; 1992; 52(6):396-400. PubMed ID: 1432936 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]